Clinical Trial Update: Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures [Phase 3]

View source ↗

Summary

An open-label extension trial evaluated the safety of USL255 in patients with refractory partial-onset seizures as part of a Phase 3 program; results were poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• USL255 (topiramate)

Snippet

Sponsor: Upsher-Smith Laboratories | Conditions: Epilepsy | Phase 3 | Status: COMPLETED | Results posted: 2015-02-23